Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study to Evaluate the Safety and Effectiveness of CD19-CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma

NCT04715217 is registered in ClinicalTrials.gov with Shanxi Province Cancer Hospital as lead sponsor.

NCT NCT04715217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04715217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study to Evaluate the Safety and Effectiveness of CD19-CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma
Lead sponsor
Shanxi Province Cancer Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 4, 2021
Completion date
October 31, 2025
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, b-cell